Evidence map›Paper›PMID 34477920›Full record

ReviewMammalian genome : official journal of the International Mammalian Genome Society2021

Inactive rhomboid proteins RHBDF1 and RHBDF2 (iRhoms): a decade of research in murine models.

Lisa M Burzenski, Benjamin E Low, Vivek Kohar, Leonard D Shultz, Michael V Wiles, Vishnu Hosur

Abstract readReview
In one paragraph

Review in Mammalian genome : official journal of the International Mammalian Genome Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. iRhom2 deletion protects against diabetic neuropathy by suppressing neuroinflammation.The Journal of pharmacology and experimental therapeutics · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. International journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lisa M BurzenskiThe Jackson Laboratory, Bar Harbor, ME, USA.
Benjamin E LowThe Jackson Laboratory, Bar Harbor, ME, USA.
Vivek KoharThe Jackson Laboratory, Bar Harbor, ME, USA.
Leonard D ShultzThe Jackson Laboratory, Bar Harbor, ME, USA.
Michael V WilesThe Jackson Laboratory, Bar Harbor, ME, USA.
Vishnu HosurThe Jackson Laboratory, Bar Harbor, ME, USA. vishnu.hosur@jax.org.ORCID http://orcid.org/0000-0003-2084-1723

Funding

Shared Resource ManagementP30CA034196 · NCI · JACKSON LABORATORY · PI William Carl Skarnes · 1985 to 2026
$61.9M
NCI NIH HHS P30 CA034196
6 · The paper itself

Abstract

Rhomboid proteases, first discovered in Drosophila, are intramembrane serine proteases. Members of the rhomboid protein family that are catalytically deficient are known as inactive rhomboids (iRhoms). iRhoms have been implicated in wound healing, cancer, and neurological disorders such as Alzheimer's and Parkinson's diseases, inflammation, and skin diseases. The past decade of mouse research has shed new light on two key protein domains of iRhoms-the cytosolic N-terminal domain and the transmembrane dormant peptidase domain-suggesting new ways to target multiple intracellular signaling pathways. This review focuses on recent advances in uncovering the unique functions of iRhom protein domains in normal growth and development, growth factor signaling, and inflammation, with a perspective on future therapeutic opportunities.

Indexed as

NeoplasmsSerine ProteasesAnimalsDisease Models, AnimalMembrane ProteinsMiceSignal TransductionMembrane ProteinsRhbdf1 protein, mouseSerine Proteases

Identifiers

PMID34477920
PMCPMC8580931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.